PharmaSGP Holding SE (XTER:PSG) ROCE % : 33.91% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PharmaSGP Holding SE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmaSGP Holding SE's annualized ROCE % for the quarter that ended in Sep. 2024 was 33.91%.

PharmaSGP Holding SE ROCE % Historical Data

The historical data trend for PharmaSGP Holding SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaSGP Holding SE ROCE % Chart

PharmaSGP Holding SE Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

23.32

26.41

86.23

27.63

24.69

PharmaSGP Holding SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															28.86	26.72	26.52	25.63	33.91

PharmaSGP Holding SE ROCE % Calculation

PharmaSGP Holding SE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	26.303	/	( ( (129.109 - 22.742)	+	(131.299 - 24.594) )	/ 2 )
	=	26.303	/	( (106.367	+	106.705)	/ 2 )
	=	26.303	/	106.536
	=	24.69 %

PharmaSGP Holding SE's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	33.104	/	( ( (134.154 - 38.646)	+	(129.516 - 29.782) )	/ 2 )
	=	33.104	/	( ( 95.508	+	99.734 )	/ 2 )
	=	33.104	/	97.621
	=	33.91 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

PharmaSGP Holding SE (XTER:PSG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmaSGP Holding SE ROCE % Related Terms

Thank you for viewing the detailed overview of PharmaSGP Holding SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaSGP Holding SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaSGP Holding SE (XTER:PSG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PSG:Germany

Address

Lochhamer Schlag 1, Graefelfing, Munich, DEU, 82166

Website

https://www.sgp-pharma.com

PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.

Executives

Dr. Clemens Fischer	Supervisory Board
Madlena Hohlefelder	Supervisory Board

PharmaSGP Holding SE Headlines

No Headlines